Decreased carbon-11-flumazenil binding in early Alzheimer's disease

Brain

Volumn 135, Issue 9, 2012, Pages 2817-2825

  Pascual, Belen ^a,b   Prieto, Elena ^c   Arbizu, Javier ^b,c   Marti Climent, Josep M ^b,c   Peñuelas, Ivan ^c   Quincoces, Gemma ^c   Zarauza, Rosina ^c   Pappatà, Sabina ^d   Masdeu, Joseph C ^a,b  

^a UNIVERSITY OF NAVARRA   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^c UNIVERSITY OF NAVARRA   (Spain)

^d CNR   (Italy)

Author keywords

Alzheimer's disease; flumazenil PET; GABA A receptors; MRI

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; FLUMAZENIL C 11; FLUORODEOXYGLUCOSE F 18;

AGED; ALZHEIMER DISEASE; ARTICLE; AUTOPSY; BRAIN METABOLISM; BRAIN REGION; BRAIN SIZE; CELL LOSS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HIPPOCAMPUS; HUMAN; IN VIVO STUDY; INFERIOR TEMPORAL CORTEX; MALE; MEMORY; NERVE CELL; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; POSTERIOR CINGULATE; PRIORITY JOURNAL; RECEPTOR BINDING; RETROSPLENIAL CORTEX; VOXEL BASED MORPHOMETRY;

EID: 84866396395     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/aws210     Document Type: Article

References (48)

1. Armstrong DM, Sheffield R, Mishizen-Eberz AJ, Carter TL, Rissman RA, Mizukami K, et al. Plasticity of glutamate and GABAA receptors in the hippocampus of patients with Alzheimer's disease. Cell Mol Neurobiol 2003; 23: 491-505.
2. Ashburner J. A fast diffeomorphic image registration algorithm. Neuroimage 2007; 38: 95-113.
3. Berkouk K, Quarantelli M, Prinster A, Landeau B, Alfano B, Baron JC. Mapping the relative contribution of gray matter activity vs. volume in brain PET: a new approach. J Neuroimaging 2006; 16: 224-35.
4. Brun A, Englund E. Regional pattern of degeneration in Alzheimer's disease: neuronal loss and histopathological grading. Histopathology 1981; 5: 549-64.
5. Chen K, Ayutyanont N, Langbaum JB, Fleisher AS, Reschke C, Lee W, et al. Characterizing Alzheimer's disease using a hypometabolic convergence index. Neuroimage 2011; 56: 52-60.
6. Chetelat G, Desgranges B, Landeau B, Mezenge F, Poline JB, de la Sayette V, et al. Direct voxel-based comparison between grey matter hypometabolism and atrophy in Alzheimer's disease. Brain 2008; 131: 60-71.
7. Chetelat G, Villemagne VL, Bourgeat P, Pike KE, Jones G, Ames D, et al. Relationship between atrophy and beta-amyloid deposition in Alzheimer disease. Ann Neurol 2010; 67: 317-24.
8. Chu DC, Penney JB Jr., Young AB. Cortical GABAB and GABAA receptors in Alzheimer's disease: a quantitative autoradiographic study. Neurology 1987; 37: 1454-9.
9. Crystal H, Dickson D, Fuld P, Masur D, Scott R, Mehler M, et al. Clinico-pathologic studies in dementia: nondemented subjects with pathologically confirmed Alzheimer's disease. Neurology 1988; 38: 1682-7.
10. Delforge J, Pappata S, Millet P, Samson Y, Bendriem B, Jobert A, et al. Quantification of benzodiazepine receptors in human brain using PET, [11C]flumazenil, and a single-experiment protocol. J Cereb Blood Flow Metab 1995; 15: 284-300.
11. Fukuchi K, Hashikawa K, Seike Y, Moriwaki H, Oku N, Ishida M, et al. Comparison of iodine-123-iomazenil SPECT and technetium-99 m-HMPAO-SPECT in Alzheimer's disease. J Nucl Med 1997; 38: 467-70.
12. Giannakopoulos P, Herrmann FR, Bussiere T, Bouras C, Kovari E, Perl DP, et al. Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer's disease. Neurology 2003; 60: 1495-500.
13. Gomez-Isla T, Hollister R, West H, Mui S, Growdon JH, Petersen RC, et al. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann Neurol 1997; 41: 17-24.
14. Gomez-Isla T, Price JL, McKeel DW Jr., Morris JC, Growdon JH, Hyman BT. Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease. J Neurosci 1996; 16: 4491-500.
15. Hammers A, Panagoda P, Heckemann RA, Kelsch W, Turkheimer FE, Brooks DJ, et al. [11C]Flumazenil PET in temporal lobe epilepsy: Do we need an arterial input function or kinetic modeling? J Cereb Blood Flow Metab 2008; 28: 207-16.
16. Heiss WD, Sobesky J, Smekal U, Kracht LW, Lehnhardt FG, Thiel A, et al. Probability of cortical infarction predicted by flumazenil binding and diffusion-weighted imaging signal intensity: a comparative positron emission tomography/magnetic resonance imaging study in early is-chemic stroke. Stroke 2004; 35: 1892-8.
17. Innis RB, Cunningham VJ, Delforge J, Fujita M, Gjedde A, Gunn RN, et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab 2007; 27: 1533-9.
18. Iwakiri M, Mizukami K, Ikonomovic MD, Ishikawa M, Abrahamson EE, DeKosky ST, et al. An immunohistochemical study of GABA A receptor gamma subunits in Alzheimer's disease hippocampus: relationship to neurofibrillary tangle progression. Neuropathology 2009; 29: 263-9.
19. Jansen KL, Faull RL, Dragunow M, Synek BL. Alzheimer's disease: changes in hippocampal N-methyl-D-aspartate, quisqualate, neuroten-sin, adenosine, benzodiazepine, serotonin and opioid receptors-an autoradiographic study. Neuroscience 1990; 39: 613-27.
20. Kalbe E, Kessler J, Calabrese P, Smith R, Passmore AP, Brand M, et al. DemTect: a new, sensitive cognitive screening test to support the diagnosis of mild cognitive impairment and early dementia. Int J Geriatr Psychiatry 2004; 19: 136-43.
21. Killiany RJ, Gomez-Isla T, Moss M, Kikinis R, Sandor T, Jolesz F, et al. Use of structural magnetic resonance imaging to predict who will get Alzheimer's disease. Ann Neurol 2000; 47: 430-9.
22. Kisvarday ZF, Gulyas A, Beroukas D, North JB, Chubb IW, Somogyi P. Synapses, axonal and dendritic patterns of GABA-immunoreactive neurons in human cerebral cortex. Brain 1990; 113 (Pt 3): 793-812.
23. Klumpers UM, Boellaard R, Veltman DJ, Kloet RW, Hoogendijk WJ, Lammertsma AA. Parametric [11C]flumazenil images. Nucl Med Commun 2012; 33: 422-30.
24. Klumpers UM, Veltman DJ, Boellaard R, Comans EF, Zuketto C, Yaqub M, et al. Comparison of plasma input and reference tissue models for analysing [(11)C]flumazenil studies. J Cereb Blood Flow Metab 2008; 28: 579-87.
25. Klumpers UM, Veltman DJ, Drent ML, Boellaard R, Comans EF, Meynen G, et al. Reduced parahippocampal and lateral temporal GABAA-[11C]flumazenil binding in major depression: preliminary results. Eur J Nucl Med Mol Imaging 2010; 37: 565-74.
26. La Fougere C, Grant S, Kostikov A, Schirrmacher R, Gravel P, Schipper HM, et al. Where in-vivo imaging meets cytoarchitectonics: the relationship between cortical thickness and neuronal density measured with high-resolution [F-18]flumazenil-PET. Neuroimage 2011; 56: 951-60.
27. Lavenex P, Suzuki WA, Amaral DG. Perirhinal and parahippocampal cortices of the macaque monkey: projections to the neocortex. J Comp Neurol 2002; 447: 394-420.
28. Massaweh G, Schirrmacher E, la Fougere C, Kovacevic M, Wangler C, Jolly D, et al. Improved work-up procedure for the production of [(18)F]flumazenil and first results of its use with a high-resolution research tomograph in human stroke. Nucl Med Biol 2009; 36: 721-7.
29. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34: 939-44.
30. Meyer M, Koeppe RA, Frey KA, Foster NL, Kuhl DE. Positron emission tomography measures of benzodiazepine binding in Alzheimer's disease. Arch Neurol 1995; 52: 314-7.
31. Misra C, Fan Y, Davatzikos C. Baseline and longitudinal patterns of brain atrophy in MCI patients, and their use in prediction of short-term conversion to AD: results from ADNI. Neuroimage 2009; 44: 1415-22.
32. Mizukami K, Ikonomovic MD, Mishizen A, Sheffield R, Grayson DR, Armstrong DM. Alterations of GABA(A)beta2/3 immunoreactivity in the dentate gyrus after perforant pathway lesion. Neuroreport 1997; 8: 3379-83.
33. Mourik JE, Lubberink M, Klumpers UM, Comans EF, Lammertsma AA, Boellaard R. Partial volume corrected image derived input functions for dynamic PET brain studies: methodology and validation for [11C]flumazenil. Neuroimage 2008; 39: 1041-50.
34. Munoz M, Insausti R. Cortical efferents of the entorhinal cortex and the adjacent parahippocampal region in the monkey (Macaca fascicularis). Eur J Neurosci 2005; 22: 1368-88.
35. Ohyama M, Senda M, Ishiwata K, Kitamura S, Mishina M, Ishii K, et al. Preserved benzodiazepine receptors in Alzheimer's disease measured with C-11 flumazenil PET and I-123 iomazenil SPECT in comparison with CBF. Ann Nucl Med 1999; 13: 309-15.
36. Okazawa H, Yamauchi H, Sugimoto K, Magata Y, Kudo T, Yonekura Y. Effects of metabolite correction for arterial input function on quantitative receptor images with 11C-flumazenil in clinical positron emission tomography studies. J Comput Assist Tomogr 2004; 28: 428-35.
37. Pappata S, Varrone A, Vicidomini C, Milan G, De Falco C, Sansone V, et al. SPECT imaging of GABA(A)/benzodiazepine receptors and cerebral perfusion in mild cognitive impairment. Eur J Nucl Med Mol Imaging 2010; 37: 1156-63.
38. Pascual B, Prieto E, Arbizu J, Marti-Climent J, Olier J, Masdeu JC. Brain glucose metabolism in vascular white matter disease with dementia: differentiation from Alzheimer disease. Stroke 2010; 41: 2889-93.
39. Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med 2004; 256: 183-94.
40. Prieto E, Marti-Climent JM, Arbizu J, Garrastachu P, Dominguez I, Quincoces G, et al. Evaluation of spatial resolution of a PET scanner through the simulation and experimental measurement of the recovery coefficient. Comp Biol Med 2010; 40: 75-80.
41. Quarantelli M, Berkouk K, Prinster A, Landeau B, Svarer C, Balkay L, et al. Integrated software for the analysis of brain PET/SPECT studies with partial-volume-effect correction. J Nucl Med 2004; 45: 192-201.
42. Rissman RA, Bennett DA, Armstrong DM. Subregional analysis of GABA(A) receptor subunit mRNAs in the hippocampus of older persons with and without cognitive impairment. J Chem Neuroanat 2004; 28: 17-25.
43. Rocher AB, Chapon F, Blaizot X, Baron JC, Chavoix C. Resting-state brain glucose utilization as measured by PET is directly related to regional synaptophysin levels: a study in baboons. Neuroimage 2003; 20: 1894-8.
44. Rousset OG, Ma Y, Evans AC. Correction for partial volume effects in PET: principle and validation. J Nucl Med 1998; 39: 904-11.
45. Sedvall G, Nyback H, Farde L, Persson A. Neurotransmitter receptor imaging in Alzheimer's disease. J Neural Transm Suppl 1987; 24: 43-8.
46. Shan ZY, Mateja SJ, Reddick WE, Glass JO, Shulkin BL. Retrospective evaluation of PET-MRI registration algorithms. J Digit Imaging 2011; 24: 485-93.
47. Shimohama S, Taniguchi T, Fujiwara M, Kameyama M. Changes in benzodiazepine receptors in Alzheimer-type dementia. Ann Neurol 1988; 23: 404-6.
48. Soricelli A, Postiglione A, Grivet-Fojaja MR, Mainenti PP, Discepolo A, Varrone A, et al. Reduced cortical distribution volume of iodine-123 iomazenil in Alzheimer's disease as a measure of loss of synapses. Eur J Nucl Med 1996; 23: 1323-8.